^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR T790M + EGFR C797S |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report
Published date:
12/29/2022
Excerpt:
A 66-year-old Taiwanese female with no history of smoking was diagnosed in July 2017 with lower upper lobe (LUL) lung adenocarcinoma...and the 19del/T790M/cis-C797S mutation was detected again by NGS from liver biopsy...we decided to start 90 mg of brigatinib once daily to alleviate bony metastasis between November 2021 and January 2022. During the therapy period, a complete response was noted over the skull (Figure 4), and a stable status was observed over lung cancer and liver metastasis.
DOI:
https://doi.org/10.3390/ijms24010602
